Lung Cancer News and Research

Latest Lung Cancer News and Research

Lung cancer clinical trials exclude substantial proportion of patients due to prior cancer

Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center.

29 Sep 2014

Study demonstrates longer-term benefits of Lung Flute for COPD patients

Patients with chronic obstructive pulmonary disease (COPD) report improved symptoms and health status when they use a hand-held respiratory device called the Lung Flute-, according to a new study by the University at Buffalo. Usually caused by smoking, COPD, which includes chronic bronchitis and emphysema, is the third leading cause of death in the U.S.

29 Sep 2014

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine to coincide with a presentation at the European Society for Medical Oncology meeting, an international research team reports that crizotinib treatment led to significant tumor shrinkage in 36 of 50 study participants and suppressed tumor growth in another 9.

29 Sep 2014

Study findings have potential to advance treatments for small cell lung cell cancer

Two recently published studies by a research team at University Hospitals Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form of lung cancer has seen no treatment advances in 30 years and "is a disease in urgent need of new drug therapies," write the study's authors.

26 Sep 2014

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress in Madrid, Spain, in 2014.

25 Sep 2014

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.

25 Sep 2014

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

A review of patients with advanced pulmonary carcinoid tumours shows that they can be responsive to chemotherapy.

24 Sep 2014

Antacids linked to reduced erlotinib efficacy

Acid suppression therapy may negatively impact outcome among patients receiving erlotinib for advanced non-small-cell lung cancer, Canadian study findings show.

24 Sep 2014

Seno Medical completes enrollment in PIONEER Pivotal Study of Imagio for diagnosing breast cancer

Seno Medical Instruments, Inc., the company pioneering the development of opto-acoustic technology as a new tool to improve the process of diagnosing breast cancer, announced today it has completed active enrollment of subjects in its U.S.-based PIONEER Pivotal Study of Imagio.

24 Sep 2014

FDG-PET technology less accurate in diagnosing lung cancer in regions where infections are common

A new analysis of published studies found that FDG-PET technology is less accurate in diagnosing lung cancer versus benign disease in regions where infections like histoplasmosis or tuberculosis are common. Misdiagnosis of lung lesions suspicious for cancer could lead to unnecessary tests and surgeries for patients, with additional potential complications and mortality.

24 Sep 2014

Alectinib promise for crizotinib-resistant NSCLC

Alectinib has shown promising antitumour activity in patients with ALK-rearranged non-small-cell lung cancer that is resistant to crizotinib, researchers report.

23 Sep 2014

Circulating tumour cell clinical research collaboration announced between EKF Diagnostics and Massachusetts General Hospital

EKF, announces that it has entered into a two year research collaboration with Massachusetts General Hospital.

From EKF Diagnostics 23 Sep 2014

Viewpoints: CHIP funding needed; GOP's flawed plan to make 'the pill' OTC; millennials' health issues

Federal financing for a beneficial health insurance program for low-income children, known as the Children's Health Insurance Program or CHIP, will run out next year unless Congress agrees to extend it. Bills are pending in both the House and the Senate to extend financing for four years, to 2019. Congress should approve the extension in the lame-duck session after the midterm elections so that families and state officials will know what the future holds. The program needs to be maintained amid uncertainty as to whether other good coverage will be available for these children (9/21).

23 Sep 2014

Olympus signs agreement with Brainlab to become exclusive U.S. distributor of Kick Navigation

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today it has reached a deal with Munich-based Brainlab to be the exclusive U.S. distributor of Kick Navigation.

From Evident Corporation - Life Sciences 22 Sep 2014

Lung Cancer News and Research

Latest Lung Cancer News and Research

Lung cancer clinical trials exclude substantial proportion of patients due to prior cancer

Study demonstrates longer-term benefits of Lung Flute for COPD patients

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Study findings have potential to advance treatments for small cell lung cell cancer

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

NCCN ORP awards four research grants to advance development of nintedanib

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

Antacids linked to reduced erlotinib efficacy

Seno Medical completes enrollment in PIONEER Pivotal Study of Imagio for diagnosing breast cancer

FDG-PET technology less accurate in diagnosing lung cancer in regions where infections are common

Alectinib promise for crizotinib-resistant NSCLC

Circulating tumour cell clinical research collaboration announced between EKF Diagnostics and Massachusetts General Hospital

Viewpoints: CHIP funding needed; GOP's flawed plan to make 'the pill' OTC; millennials' health issues

Olympus signs agreement with Brainlab to become exclusive U.S. distributor of Kick Navigation

Disrupting cancer regulator MYC: an interview with Professor Kim Janda

Ramucirumab effective second-line option for NSCLC

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

S-1 plus radiotherapy shows promise in elderly NSCLC patients

Lobectomy and segmentectomy have similar efficacy in stage I NSCLC

The ultimate guide to lung research tools and protocols eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in